Compare · ABBV vs UPC
ABBV vs UPC
Side-by-side comparison of AbbVie Inc. (ABBV) and Universe Pharmaceuticals Inc. (UPC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and UPC operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $466.45B, about 19102.2x UPC ($24.4M).
- Over the past year, ABBV is up 18.6% and UPC is down 10.0% - ABBV leads by 28.6 points.
- ABBV has been more active in the news (15 items in the past 4 weeks vs 2 for UPC).
- ABBV has more recent analyst coverage (25 ratings vs 0 for UPC).
- Company
- AbbVie Inc.
- Universe Pharmaceuticals Inc.
- Price
- $263.86-0.08%
- $4.03-1.35%
- Market cap
- $466.45B
- $24.4M
- 1M return
- -0.84%
- -28.25%
- 1Y return
- +18.63%
- -9.96%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- 2021
- News (4w)
- 15
- 2
- Recent ratings
- 25
- 0
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Universe Pharmaceuticals Inc.
Universe Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment and relief for common chronic health conditions in the elderly for the physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party producers, including biomedical drugs, medical instruments, traditional Chinese medicine pieces products, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was incorporated in 2019 and is based in Ji'an, China. Universe Pharmaceuticals INC operates as a subsidiary of Sununion Holding Group Limited.
Latest ABBV
- AbbVie Highlights New Real-World Data Supporting the Effectiveness of VRAYLAR® (cariprazine) at Psych Congress 2026
- AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society (IMS) Meeting
- Allergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss Medications
- AbbVie and BioLabs University of Toronto Open Applications for AbbVie Biotech Innovators Award at Life Sciences Ontario Forum
- Allergan Aesthetics to Advance Scientific Dialogue on Skin Longevity, Aging Biology and Exosome Science at the 2026 Science of Skin Summit
- AbbVie Declares Quarterly Dividend
- AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine
- AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma
- AbbVie Inc. filed SEC Form 8-K: Regulation FD Disclosure
- AbbVie Completes Acquisition of Apogee Therapeutics
Latest UPC
- Amendment: SEC Form 6-K/A filed by Universe Pharmaceuticals Inc.
- SEC Form 6-K filed by Universe Pharmaceuticals Inc.
- SEC Form 6-K filed by Universe Pharmaceuticals Inc.
- SEC Form 6-K filed by Universe Pharmaceuticals Inc.
- 4 Sizzling Biotech and Healthcare Companies Reporting Strategic Milestones
- SEC Form 6-K filed by Universe Pharmaceuticals Inc.
- Universe Pharmaceuticals INC Announces Strategic Acquisition to Expand Pharmaceutical Patent Portfolio
- Chief Executive Officer Lai Gang was granted 71,890 units of Class A ordinary shares and was granted 12,610 units of Class B ordinary shares (SEC Form 4)
- SEC Form 6-K filed by Universe Pharmaceuticals Inc.
- SEC Form 6-K filed by Universe Pharmaceuticals Inc.